FDA grants orphan drug designation to IKT-001 for PAH

The FDA granted orphan drug designation to IKT-001 for treating patients with pulmonary arterial hypertension, according to a press release from Inhibikase Therapeutics.IKT-001 (Inhibikase Therapeutics) is a prodrug of imatinib mesylate, and the release highlighted that the designation applies to imatinib because it is the active moiety of IKT-001.